In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.
|Videos|May 18, 2020
Evaluating Favipiravir For COVID 19
Author(s)Contagion® Editorial Staff
Armand Balboni, MD, PHD, CEO of Appili Therapeutics, discusses work with favipiravir on a new front for the drug — the global search for COVID-19 treatment and prevention therapies.
Advertisement
Segment Description: Armand Balboni, MD, PHD, CEO of Appili Therapeutics, discusses the firm's work with favipiravir on a new front for the drug — the global search for COVID-19 treatment and prevention therapies.
Dr. Armand Balboni, CEO of Appili Therapeutics has announced that his company is working with FUJIFILM Toyama Chemical on its favipiravir treatment, which is approved in Japan as an antiviral drug, on a new front for the drug — the global search for a pandemic treatment that can both prevent and treat COVID-19
Appili Therapeutics will sponsor the first clinical trial, phase 2, evaluating favipiravir for the prevention of COVID-19, as it has shown early efficacy against this disease. Appili is working with Canadian government agencies and infectious disease specialists to conduct the clinical trial at multiple long-term care facilities across Ontario.
Dr. Balboni worked with the drug when he was with the US department of defense and with the FDA during the pandemic flu and Ebola outbreaks. The treatment is administered orally, and not by injection, making it easier on patients.
Advertisement
Related to this article
Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.
Deborah Fuller, PhD, provides commentary around the data, and advantages of the technology.
Confirmed US measles cases rose 6.8% this week to 5,182, more than double the 2025 total, as three states reported measles-associated deaths.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Advertisement
Advertisement